Esperion Welcomes New Board Member Craig Thompson
ANN ARBOR, Mich. — Esperion (NASDAQ: ESPR) is excited to announce the appointment of Craig Thompson, the Chief Executive Officer of Cerevance, to its Board of Directors as an independent director. With his addition, Esperion strengthens its leadership team, now consisting of eight members dedicated to advancing the company's mission.
A Warm Welcome to Craig Thompson
Sheldon Koenig, President and CEO of Esperion, expressed enthusiasm about Craig's appointment, noting, "We are thrilled to welcome Craig to our Board of Directors. He brings over twenty years of experience in the biopharmaceutical sector, along with a proven record of developing innovative therapies. His insights and expertise will be instrumental as we strive to strengthen our position in cardiovascular and cardiometabolic drug development."
Craig Thompson's Vision
In his statement, Mr. Thompson shared, "I am honored to join the Board of Esperion, a company pushing the boundaries in cardiovascular disease prevention. Cardiovascular conditions are the leading cause of death worldwide, highlighting an urgent need for innovative solutions. I look forward to collaborating with this impressive team to guide strategic decisions and foster the development of impactful, science-driven solutions that can enhance patients' lives."
Craig Thompson's Impressive Background
Before joining Esperion's Board, Mr. Thompson served as the Chief Executive Officer and board member of Cerevance, specializing in therapies for neurodegenerative disorders since April 2022. He also sits on the board of NervGen Pharma Corp, focusing on treatments for neurotrauma and neurological diseases. His previous roles include President and Chief Executive Officer at Neurana Pharmaceuticals and a significant tenure at Anthera Pharmaceuticals Inc. His expertise stretches across notable positions like Chief Operating Officer at Tetraphase Pharmaceuticals and Chief Commercial Officer at Trius Therapeutics, where he played a key role in a successful acquisition by Cubist Pharmaceuticals.
Experience with Industry Leaders
Mr. Thompson's extensive career includes various leadership roles at Pfizer Inc., where he oversaw multiple therapeutic areas, including Allergy and Inflammation. He ultimately became the Vice President of Marketing for Pfizer's Specialty Care Business Unit. His early career also includes a significant position in global marketing at Merck & Co., notably managing Zocor® and contributing to the pre-launch planning for Vytorin® and Zetia®.
Esperion's Commitment to Innovation
Esperion Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing cutting-edge medications that meet the unmet needs of patients and healthcare professionals. The company has introduced the only FDA-approved oral, once-daily, non-statin medications for patients who face risks associated with cardiovascular disease while struggling with high levels of low-density lipoprotein cholesterol (LDL-C). These groundbreaking medications have the backing of the significant CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients.
Future Endeavors and Pipeline Development
Looking ahead, Esperion is actively advancing its next-generation programs focused on developing ATP citrate lyase inhibitors (ACLYi). Recent understanding of ACLYi has opened doors for the design of highly specific and potent inhibitors using allosteric mechanisms, representing a considerable leap forward in therapeutic capabilities.
As Esperion continues to grow as an influential global biopharmaceutical entity, it is committed to achieving excellence through strategic commercial execution and fostering international partnerships. This focus not only enhances its current offerings but also propels advancement in its preclinical pipeline.
Frequently Asked Questions
1. Who is Craig Thompson?
Craig Thompson is the Chief Executive Officer of Cerevance and has extensive experience in the biopharmaceutical industry. He has recently joined Esperion's Board of Directors as an independent member.
2. What is Esperion's main focus?
Esperion is dedicated to developing and commercializing innovative biopharmaceuticals that address unmet patient needs, particularly in cardiovascular and cardiometabolic health.
3. What are the notable achievements of Esperion?
Esperion has developed the only FDA-approved oral, once-daily, non-statin medications for patients at risk for cardiovascular issues, validated by vast clinical outcomes.
4. How does Craig Thompson contribute to Esperion?
With his profound understanding of biopharmaceutical commercialization and clinical development, Mr. Thompson will provide strategic insights and operational expertise as Esperion grows.
5. What is the future initiative of Esperion?
Esperion aims to advance its pipeline with innovative programs focusing on ATP citrate lyase inhibitors, harnessing scientific insights for better healthcare solutions.
